Related Experiment Video

Updated: Mar 1, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.2K

New treatment directions for IPF: current status of ongoing and upcoming clinical trials

Francesco Macagno1, Francesco Varone1, Paolo Maria Leone1

  • 1a Università Cattolica del Sacro Cuore, Unità Operativa Complessa di Pneumologia , Fondazione Policlinico A. Gemelli , Rome , Italy.

Expert Review of Respiratory Medicine
|May 26, 2017
PubMed
Abstract

Insights

This review explores new clinical trials for idiopathic pulmonary fibrosis (IPF), examining novel therapies targeting matrix deposition, immunity, autoimmunity, stem cells, and the microbiome. Future trials must refine patient selection and endpoints for personalized medicine approaches.

Area of Science:

  • Pulmonary Medicine
  • Fibrotic Lung Diseases
  • Clinical Trial Research

Background:

  • Idiopathic pulmonary fibrosis (IPF) treatment options are expanding beyond approved drugs like pirfenidone and nintedanib.
  • New biological pathways are being investigated for therapeutic intervention in IPF.
  • Understanding the role of immunity, autoimmunity, and the microbiome in IPF is crucial.

Purpose of the Study:

  • To provide a comprehensive overview of emerging clinical trials in IPF.
  • To explore novel therapeutic strategies and their potential impact on IPF treatment.
  • To analyze the future landscape of IPF therapy, including personalized medicine.

Main Methods:

  • Review of current and upcoming clinical trials in idiopathic pulmonary fibrosis.
  • Analysis of research into new biological targets and therapeutic approaches.
  • Examination of advancements in stem cell therapy and microbiome research for IPF.

Main Results:

  • Approved IPF drugs pirfenidone and nintedanib efficacy is confirmed.
  • New strategies targeting matrix deposition, immunity, autoimmunity, stem cells, and microbiome are under investigation.
  • Emerging therapies offer new possibilities for IPF treatment and lung tissue recovery.

Conclusions:

  • Future IPF clinical trials require careful selection of patient populations and efficacy endpoints.
  • Progressive fibrotic lung diseases, including IPF, may benefit from refined trial designs.
  • Integrating existing therapies into personalized medicine frameworks remains a key challenge for IPF treatment.
Keywords:
Idiopathic pulmonary fibrosisautoimmunitycombination therapyimmunitylung microbiomamesenchymenovel targetsstem cells

More Related Videos

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

1.1K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.0K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
556
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
599
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
671
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
511